**2.1 Pulmonary complications**

Torres-Cuevas et al. [20] report studies suggesting that approximately 40% of the population infected by SARS-CoV-2 and Middle East Respiratory Syndrome (MERS) presented radiological changes and data suggestive of pulmonary fibrosis, which were associated with respiratory alteration, even 15 years after the infection. The same authors mention the following risk factors:


Torres-Cuevas et al. [20] reported that as many as one-third of COVID-19 patients exhibit signs of pulmonary fibrosis and lung function abnormalities 3 months after COVID-19. Pulmonary fibrosis is relevant because it is associated with higher morbidity and mortality. It may also be considered the most significant health sequel of the pandemic since it requires the implementation of pulmonary rehabilitation techniques [20].

Similarly, it has been identified that respiratory symptoms due to COVID-19 can persist even 110 days after the acute picture, the most frequent being chest pain, anosmia, cough, and dyspnea [20].
